Work

Sorafenib-Induced Eruptive Melanocytic Lesions

Year: 2008

Type: article

Abstract: We report 2 cases of eruptive melanocytic lesions associated with sorafenib, a multikinase inhibitor FDA-approved for the treatment of advanced renal cell carcinoma.Understanding the development of this previously unknown side effect may provide further insight into sorafenib's mechanistic effects on tumors and normal tissues and into the development of pigmented lesions.

Source: Archives of Dermatology

DOI: 10.1001/archderm.144.6.820

Authors: Heidi H. Kong, Vincent Sibaud, Maria L. Chanco Turner, Tito Fojo, Thomas J. Hornyak, Christine Chevreau

Institutions: National Institutes of Health, National Cancer Institute, Institut Claudius Regaud

Language: English

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: National Institutes of Health